Reminder: Upcoming Changes to the Medicaid Fee-for-Service Claim Submission Process for Practitioner-Administered Drugs

October 19, 2026

What Is Happening?

Changes are coming to practitioner-administered drugs (PADs). **Effective November 19, 2026**, NYRx, the Medicaid Drug Program, will introduce electronic clinical editing to confirm prior authorization (PA) requirements for select PADs for members with Fee-For-Service (FFS) medical coverage. The phased, iterative approach will align clinical editing and utilization management across NYRx Medicaid drug programs. Detailed information about the PA change is available in the New York State Medicaid Update - September 2026 Practitioner-Administered Drug Modernization - Part 2: Prior Authorization Changes for Select Drugs in New York State Medicaid Fee-for-Services Special Edition Volume 42 - Number 10. NYRx will proactively announce each phase, including the affected drugs and clinical criteria, to support a smooth transition for FFS providers.

The drugs and/or drug classes included in Phase 1 are as follows:

- **Botulinum toxin agents:**
  - onabotulinumtoxinA (Botox®)
  - abobotulinumtoxinA (Dysport®)
  - rimabotulinumtoxinB (Myobloc®)
  - incobotulinumtoxinA (Xeomin®)
  - daxibotulinutoxinA (Daxxify®)
- **Infliximab agents:**
  - infliximab (Remicade®)
  - infliximab-abda (Renflexis®)
  - infliximab-axxq (Avsola®)
  - infliximab-dyyb (Inflectra®)
  - infliximab-dyyb (Zymfentra®)

- **Treatment-resistant depression:**
  - esketamine nasal spray (Spravato®)
- **Spinal muscular atrophy (SMA):**
  - nusinersen (Spinraza®)
- **Duchenne muscular dystrophy (DMD):**
  - casimersen (Amondys 45™)
  - eteplirsen (Exondys 51™)
  - viltolarsen (Viltepso™)
  - golodirsen (Vyondys 53™)

In addition to electronic clinical editing, the pricing benchmarks used to determine the maximum reimbursable amount for drugs in this setting will be changing. Detailed information about the reimbursement changes is available in the New York State Medicaid Update - March 2026 Reimbursement Change for New York State Medicaid Fee-for-Service Professional Drug Claims Special Edition Volume 42 - Number 3.

Note: These changes do not apply to members who receive their medical benefits through Medicaid Managed Care Organizations (MCOs). New York Medicaid members who are enrolled in a MCO will continue to receive their medical benefits and PAD PAs via their MCO. Providers should review the NYS Department of Health "Medicaid Managed Care Plan Information" web page for MCO-specific requirements.

What Prescribers and Billing Staff Need to Do

Prescribers and billing staff are affected by this change and will need to update processes for claim submission and PA requests for their New York Medicaid FFS members. Prescribers and billing staff should also be aware of pricing benchmarks and reimbursement changes.

Providers must obtain an approved PA **before** administering the drug to the member. Failure to obtain a PA prior to administration may result in non-payment. To obtain PA, the provider can use PAXpress™ or CoverMyMeds.

The NYRx Education & Outreach (E&O) team, in partnership with NYSDOH, will be providing additional information and resources to support prescribers and billing staff with these changes. The team will also conduct targeted outreach to prescribers who have a recent claim for an impacted PAD to notify them of this change. To stay up to date with resources from the NYRx E&O team, subscribe to the NYRx Education & Outreach Notification Service.

Resources

- New York Medicaid Fee-For Service (FFS) Practitioner-Administered Drug (PAD) Prior Authorization (PA) Program Quick Reference Guide
- New York State Medicaid Update - March 2026 Reimbursement Change for New York State Medicaid Fee-for-Service Professional Drug Claims Special Edition Volume 42 - Number 3
- New York State Medicaid Update - September 2026 Practitioner Administered Drug Modernization - Part 2: Prior Authorization Changes for Select Drugs in New York State Medicaid Fee-for-Services Special Edition Volume 42 - Number 10
- NYRx Education & Outreach Website
- NYRx Preferred Drug Lists
- Prior Authorization for Practitioner-Administered Drugs One Sheet

Contact Information

The NYRx Education & Outreach Call Center is available by phone at 1-833-967-7310 or by email at NYRxEO@primetherapeutics.com from 8:00 AM to 5:00 PM ET, Monday through Friday, excluding holidays.

For questions related to New York State Medicaid FFS billing or claims, call the eMedNY Call Center at 1-800-343-9000.

For questions related to New York State Medicaid FFS drug policy, email NYRx@health.ny.gov.